Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Regenall Limited currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio is concentrated under 1 distinct examiner and 1 distinct art unit, reflecting a focused stage of patent activity. This singular focus means that the company's current interactions with the patent office are limited to one specific technical and administrative channel. The presence of 1 distinct art unit allows the applicant to concentrate their technical arguments within a single specialized group.
The busiest examiner for this portfolio is IVANOVA, SVETLANA M, who is responsible for 1 pending office action. This 1 pending office action represents the total pending volume for Regenall Limited at this time. With 1 distinct art unit involved, the technical review is confined to a specific area of biotechnology. This allows for a targeted prosecution strategy that can be tailored to the specific feedback and examination style of IVANOVA, SVETLANA M, simplifying the overall management of the pending matter. Practitioners should focus on the specific requirements of this examiner to advance the 1 pending office action effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923105 | VITAMIN A FOR USE IN THE TREATMENT OF TRAUMATIC BRAIN INJURY | IVANOVA, SVETLANA M | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17923105 | VITAMIN A FOR USE IN THE TREATMENT OF TRAUMATIC BRAIN INJURY | IVANOVA, SVETLANA M | 1627 | §103 | Final Rejection | 4d overdue | Pending | Nov 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial